Taltz Eases Disease Activity, Improves Quality of Life in nr-axSpA Patients, Phase 3 Trial Shows
News
Treatment with the anti-rheumatic drug Taltz (ixekizumab) leads to early and sustained reductions in pain, fatigue, and inflammation in people with non-radiographic axial spondyloarthritis (nr-axSpA), a Phase 3 trial ... Read more